The Global Intestinal Fistula Treatment Industry is expected to reach US$ 46.82 billion by 2033, with a CAGR of 5.8%. This increase is due to ongoing advances in pharmaceuticals and innovation, which pave the path for transformational therapies in the intestinal fistula environment.
The market is expected to be valued at US$ 26.64 billion in 2023, indicating a substantial start to a decade-long development trajectory. The rising prevalence of ulcerative colitis and Crohn’s disease, together with increased global awareness of these illnesses, is driving this expansion.
One of the key catalysts behind the projected market growth is the intensification of research and development activities within the industry. Leading players are fervently exploring novel candidates for the treatment of intestinal fistula, steering the industry toward groundbreaking solutions.
Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16376
Moreover, the increasing demand for biologics for treating these conditions has influenced market players to expand their portfolios and commercialize their drugs globally. Thus, the rising regulatory approvals for the drugs launched by the key players and increasing patients’ preferences for the medications are also expected to contribute to the market growth in the coming time. An increase in awareness about intestinal fistula treatment, and a rise in several hospitalization cases of the disease are the key factors that are expected to accelerate the market growth. An article published by NCBI (2020) stated that ulcerative colitis has an incidence of 9 to 20 cases per 100,000 per year. Hence, the aforementioned factors are likely to increase the revenue share of the market in the forthcoming years.
Key Takeaways from the Global Intestinal Fistula Treatment Industry Study
- The global intestinal fistula treatment market was valued at US$ 25.18 Billion by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 2%
- By drug class, proton-pump inhibitors to yield 45% revenue in the global intestinal fistula treatment market
- By distribution channel, the hospital pharmacies segment dominates the market with a share of 46%
- From 2023 to 2033, intestinal fistula treatment worth is expected to flourish at a CAGR of 8%.
- By 2033, the market value of Intestinal Fistula Treatment is expected to reach US$ 82 Billion
“An upsurge in financial support to researchers for developing new innovative drugs for treatment of intestinal fistula, coupled with increasing prevalence of Crohn’s disease are expected to fuel the Intestinal Fistula Treatment Market in the forthcoming years,” remarks an FMI analyst.
Competitive Landscape:
Prominent players in the intestinal fistula treatment market are Livealth BioPharma, Boehringer Ingelheim International GmbH, Pfizer Inc., Apsolabs, AstraZeneca, Pipelinepharma, Astellas Pharma Inc., Caspian Tamin Pharmaceutical Company, Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Merck & Co. KGaA and Moderna Inc.
Buy a Complete Research Report
https://www.futuremarketinsights.com/checkout/16376
Recent Developments:
- In May 2021, Bristol Myers Squibb announced that the Food and Drug Administration (FDA) approved Zeposia (ozanimod) for the treatment of moderate to severe active ulcerative colitis in adults
- In September 2019, Janssen Biotech, Inc.’s product, STELARA, was approved for the treatment of moderate to severe active ulcerative colitis in the European Union
- In April 2019, Salix Pharmaceuticals entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to commercialize and develop late stage investigational S1P modulator for the treatment of inflammatory bowel disease
- In October 2018, Allergan launched a personalized study approach for clinical research programs in inflammatory bowel disease. These programs would evaluate the efficacy and safety of brazikumab and the potential correlation between biomarkers and patient outcomes with brazikumab.
Key Segments Covered in the Global Intestinal Fistula Treatment Industry Analysis
By Drug Class:
- Anticholinergic
- Proton-Pump Inhibitors
- H2 Blockers
- Antidiarrheals
By Route of Administration:
- Oral
- Parenteral
- Rectal
- Transdermal
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Clinical Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
